{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:15:53Z","timestamp":1791292553380,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.berh.2008.09.008","type":"journal-article","created":{"date-parts":[[2008,11,26]],"date-time":"2008-11-26T12:14:46Z","timestamp":1227701686000},"page":"847-861","source":"Crossref","is-referenced-by-count":236,"title":["Autoimmune diseases induced by TNF-targeted therapies"],"prefix":"10.1016","volume":"22","author":[{"given":"Manuel","family":"Ramos-Casals","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Brito-Zer\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Jose","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Jose","family":"Cuadrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munther A.","family":"Khamashta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2008.09.008_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.semarthrit.2005.01.003","article-title":"Differentiating the efficacy of the tumor necrosis factor inhibitors","volume":"34","author":"Haraoui","year":"2005","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2008.09.008_bib2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003495-200565050-00006","article-title":"Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis","volume":"65","author":"Nurmohamed","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.berh.2008.09.008_bib3","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/j.berh.2008.09.008_bib4","first-page":"1232","article-title":"Long-term safety, efficacy and radiographic outcomes with etanercept treatment in patients with early rheumatoid arthritis","volume":"32","author":"Genovese","year":"2005","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.berh.2008.09.008_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jaad.2004.10.788","article-title":"Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis","volume":"52","author":"Lebwohl","year":"2005","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.berh.2008.09.008_bib6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/01.bor.0000198007.73320.6e","article-title":"Musculoskeletal manifestations and autoimmune diseases related to new biologic agents","volume":"18","author":"Haraoui","year":"2006","journal-title":"Current Opinion in Rheumatology"},{"key":"10.1016\/j.berh.2008.09.008_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.tox.2004.12.025","article-title":"Drug-induced lupus","volume":"209","author":"Rubin","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.berh.2008.09.008_bib8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.berh.2008.09.008_bib9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/0003-4819-137-7-200210010-00030","article-title":"Infliximab-induced systemic lupus erythematosus","volume":"137","author":"Ali","year":"2002","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.berh.2008.09.008_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard.2004.024182","article-title":"Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha","volume":"64","author":"Eriksson","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2008.09.008_bib11","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2008.09.008_bib12","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1136\/ard.61.11.1031","article-title":"New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis","volume":"61","author":"Cairns","year":"2002","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2008.09.008_bib13","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1191\/0961203302lu236cr","article-title":"Drug-induced lupus following treatment with infliximab in rheumatoid arthritis","volume":"11","author":"Favalli","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2008.09.008_bib14","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0889-857X(05)70239-8","article-title":"Drug-induced vasculitis","volume":"27","author":"Merkel","year":"2001","journal-title":"Rheumatic Diseases Clinics of North America"},{"key":"10.1016\/j.berh.2008.09.008_bib15","first-page":"56","article-title":"Clinical approach to cutaneous vasculitis","volume":"17","author":"Gonzalez-Gay","year":"2005","journal-title":"Current Opinion in Rheumatology"},{"key":"10.1016\/j.berh.2008.09.008_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/01.md.0000216817.35937.70","article-title":"Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients","volume":"85","author":"Ramos-Casals","year":"2006","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.berh.2008.09.008_bib17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides. Proposal of an international consensus conference","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2008.09.008_bib18","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2008.09.008_bib19","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-142-8-200505030-00011","article-title":"Wegener's Granulomatosis Etanercept Trial Research Group. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of thrombosis (WeCLOT) Study","volume":"142","author":"Merkel","year":"2005","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.berh.2008.09.008_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semarthrit.2007.05.004","article-title":"The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review","volume":"37","author":"Grinblat","year":"2008","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2008.09.008_bib21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keg263","article-title":"Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy","volume":"42","author":"Kroesen","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2008.09.008_bib22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.rdc.2004.01.003","article-title":"Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments","volume":"30","author":"Bieber","year":"2004","journal-title":"Rheumatic Diseases Clinics of North America"},{"key":"10.1016\/j.berh.2008.09.008_bib23","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2008.09.008_bib24","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2008.09.008_bib25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/ard.61.6.565","article-title":"Silent thyroiditis associated with etanercept in rheumatoid arthritis","volume":"61","author":"Andr\u00e9s","year":"2002","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2008.09.008_bib26","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2008.09.008_bib27","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","article-title":"Drug-induced systemic lupus erythematosus associated with etanercept therapy","volume":"359","author":"Shakoor","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2008.09.008_bib28","doi-asserted-by":"crossref","first-page":"R666","DOI":"10.1186\/ar1724","article-title":"Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study","volume":"7","author":"Flendrie","year":"2005","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.berh.2008.09.008_bib29","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2008.09.008_bib30","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/ard.2007.081679","article-title":"Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis","volume":"67","author":"Pu\u00e9chal","year":"2008","journal-title":"Annals of the Rheumatic Diseases"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694208001058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694208001058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T06:42:59Z","timestamp":1632379379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694208001058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S1521694208001058"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2008.09.008","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}